Because of new findings about next-day somnolence and sex differences in zolpidem clearance, the FDA has recommended lower doses of the drug, particularly for women, and emphasizes the greater risk of impairment with modified-release than with immediate-release formulations.
No takes yet. Share an insight, caveat, or question.
Farkas et al. (2013) studied this question.